Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.

Kang S, Kim B, Park SB, Jeong G, Kang HS, Liu R, Kim SJ.

Int J Oncol. 2013 Nov;43(5):1659-65. doi: 10.3892/ijo.2013.2094. Epub 2013 Sep 10.

PMID:
24026393
2.

Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.

Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF.

Breast Cancer Res. 2008;10(4):R62. doi: 10.1186/bcr2121. Epub 2008 Jul 18.

3.

Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.

Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, Gazdar AF.

Clin Cancer Res. 2003 Dec 15;9(17):6389-94.

4.

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.

5.

Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer.

Kim JH, Kang HS, Kim TW, Kim SJ.

Int J Oncol. 2011 Oct;39(4):955-63. doi: 10.3892/ijo.2011.1075. Epub 2011 Jun 14.

PMID:
21674123
6.

Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.

Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2010 Feb;119(3):601-12. doi: 10.1007/s10549-009-0339-8. Epub 2009 Mar 20.

PMID:
19301122
7.

DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.

Roll JD, Rivenbark AG, Jones WD, Coleman WB.

Mol Cancer. 2008 Jan 25;7:15. doi: 10.1186/1476-4598-7-15.

8.

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151. Epub 2008 Sep 30.

9.

Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.

Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF.

Clin Cancer Res. 2001 Jul;7(7):1998-2004.

10.

Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2005 Feb 15;11(4):1380-5.

11.

Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.

Pakneshan P, Têtu B, Rabbani SA.

Clin Cancer Res. 2004 May 1;10(9):3035-41.

12.

Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.

Ramos EA, Camargo AA, Braun K, Slowik R, Cavalli IJ, Ribeiro EM, Pedrosa Fde O, de Souza EM, Costa FF, Klassen G.

BMC Cancer. 2010 Jan 28;10:23. doi: 10.1186/1471-2407-10-23.

13.

Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.

Radpour R, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus M, Bitzer J, Lefkovits I, Staedtler F, Zhong XY.

PLoS One. 2011;6(11):e27355. doi: 10.1371/journal.pone.0027355. Epub 2011 Nov 4.

14.

Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.

Jiang Y, Tong D, Lou G, Zhang Y, Geng J.

Pathobiology. 2008;75(4):244-51. doi: 10.1159/000132385. Epub 2008 Jun 26.

PMID:
18580070
15.
16.

Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.

Baba S, Hara A, Kato K, Long NK, Hatano Y, Kimura M, Okano Y, Yamada Y, Shibata T.

Oncol Rep. 2009 Nov;22(5):1173-9.

PMID:
19787237
17.

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG.

J Natl Cancer Inst. 2000 Apr 5;92(7):564-9.

PMID:
10749912
18.

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.

Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD.

PLoS Med. 2006 Dec;3(12):e486.

19.

Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.

Xie XM, Zhang ZY, Yang LH, Yang DL, Tang N, Zhao HY, Xu HT, Li QC, Wang EH.

Int J Oncol. 2013 Nov;43(5):1636-42. doi: 10.3892/ijo.2013.2084. Epub 2013 Aug 29.

PMID:
24002585
20.

Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.

Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, Liang X, Wei W, Sun S, Zhang Y, Liu XS, Song Q, Yang Y, Ma Y, Liu Y, Yang L, Ren Y, Zhang G, Pang D.

PLoS One. 2013;8(1):e53931. doi: 10.1371/journal.pone.0053931. Epub 2013 Jan 21.

Supplemental Content

Support Center